# 2025-08876: President Orders Fair Drug Prices Like in Europe—Finally! 2025-08876, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients, is a Federal Register presidential document from Executive Office of the President published 2025-05-15, effective 2025-05-12; PRIA reads it as touching household money (as of 2026-11-03). - Canonical: https://policyrisk.com/federal-register/2025-08876 - As of: 2026-11-03 - Plain-text twin of the page above; the HTML and this file carry the same facts. ## Facts - Document number: 2025-08876 - Title: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients - Type: Presidential Document - Agencies: Executive Office of the President - Citation: 90 FR 20749 - Published: 2025-05-15 - Effective: 2025-05-12 - Comments close: not stated - Significant: no - Touches household money: yes - Regulation identifier numbers: none - Last updated: 2026-11-03 ## In one line President Orders Fair Drug Prices Like in Europe—Finally! ## Summary Starting soon, Americans will pay the lowest prices for prescription drugs—just like other rich countries do! This change targets drug makers who charge U.S. patients way more than folks overseas. By making drug prices fairer, this order aims to save money for patients and the government, with new rules rolling out quickly. ## Effects PRIA read - Administration Sets Most-Favored-Nation Targets: benefit, high. The Secretary of Health and Human Services must communicate most-favored-nation (MFN) price targets to drug manufacturers within 30 days of May 12, 2025. The goal is to bring U.S. drug prices in line with comparably developed nations by giving manufacturers specific MFN price targets. - Direct-to-Consumer Purchase Programs Enabled: benefit, medium. To the extent allowed by law, the Secretary of Health and Human Services will facilitate direct-to-consumer purchasing programs for manufacturers that sell drugs to American patients at the most-favored-nation price. This is intended to let patients buy medicines directly at lower MFN prices when m… - Possible Importation Waivers to Cut Drug Costs: benefit, high. If MFN pricing progress is not achieved, the Secretary may consider certifying to Congress that importation under section 804(j) of the Federal Food, Drug, and Cosmetic Act poses no additional health risk and would result in a significant reduction in cost. If the Secretary certifies, the FDA Commi… - Antitrust Enforcement Against Drug Industry Practices: benefit, medium. Following a report required by an earlier executive order (the April 15, 2025 report), the Attorney General and the Federal Trade Commission shall, to the extent consistent with law, pursue enforcement against identified anti-competitive practices using tools like the Sherman Act and FTC Act. This… - FDA Review and Possible Revocation of Drug Approvals: benefit, low. The FDA Commissioner is directed to review and potentially modify or revoke approvals for drugs that may be unsafe, ineffective, or improperly marketed. This directs the agency to reconsider approvals where safety, effectiveness, or marketing issues are identified. - Trade Actions to Address Foreign Price Suppression: benefit, medium. The Secretary of Commerce and the U.S. Trade Representative are directed to take necessary action to address foreign acts, policies, or practices that suppress pharmaceutical prices below fair market value or otherwise force U.S. patients to pay disproportionate shares of R&D costs. The order instr… ## Related documents - [2026-22385](https://policyrisk.com/federal-register/2026-22385): Adjusting Imports of Robotics, Industrial Machinery, and Their Parts and Components Into the United States, 2026-11-02 - [2026-22292](https://policyrisk.com/federal-register/2026-22292): Further Modifying the Scope of Products of Canada Subject to the Additional Duties Imposed To Offset Canadian Discrimination Against the Co…, 2026-10-30 - [2026-22051](https://policyrisk.com/federal-register/2026-22051): Decreasing Housing Costs for the American People, 2026-10-28 - [2026-22052](https://policyrisk.com/federal-register/2026-22052): Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Domestic Petroleum Production, Ref…, 2026-10-28 - [2026-22049](https://policyrisk.com/federal-register/2026-22049): Adjusting Imports of Wind Turbines and Their Parts and Components Into the United States, 2026-10-28 - [2026-22050](https://policyrisk.com/federal-register/2026-22050): National Seafood Month, 2026, 2026-10-28 ## Sources - [2025-08876 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/15/2025-08876/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients) - [2025-08876 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-15/pdf/2025-08876.pdf) ## Related - [Previous: 2025-08786, Continuation of the National Emergency With Respect to the Stabilization of Iraq](https://policyrisk.com/federal-register/2025-08786) - [Next: 2025-09229, Peace Officers Memorial Day and Police Week, 2025](https://policyrisk.com/federal-register/2025-09229) - [All Federal Register documents](https://policyrisk.com/federal-register) Source: PRIA, https://policyrisk.com/federal-register/2025-08876 (as of 2026-11-03).